End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
189,000 KRW | +2.89% | +5.76% | -6.20% |
Apr. 24 | Market Share of Celltrion’s Remsima Rises to 74% in Europe | MT |
Apr. 17 | Celltrion, Inc. announces an Equity Buyback for 436,047 shares. | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- The company is in a robust financial situation considering its net cash and margin position.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 73.17 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-6.20% | 28.31B | C | ||
+0.17% | 42.19B | B | ||
+10.92% | 42.24B | B- | ||
+44.30% | 40.15B | A | ||
+5.23% | 24.63B | B- | ||
-24.79% | 18.2B | B | ||
+26.69% | 12.01B | C+ | ||
-3.13% | 11.76B | C+ | ||
+6.57% | 10.4B | B+ | ||
-18.08% | 9.94B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- A068270 Stock
- Ratings Celltrion, Inc.